Last reviewed · How we verify
IDEC-114
At a glance
| Generic name | IDEC-114 |
|---|---|
| Sponsor | Biogen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma (PHASE2)
- Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma (PHASE2)
- Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL) (PHASE3)
- A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) (PHASE3)
- Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma (PHASE1, PHASE2)
- Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma (PHASE1, PHASE2)
- Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDEC-114 CI brief — competitive landscape report
- IDEC-114 updates RSS · CI watch RSS
- Biogen portfolio CI